Pricing: Free for Members and Non-Members

• Webinar Recording
  Recording of April 29, 2025 Live Webinar
• Thursday, May 15, 2025 at 2-3pm ET
  Live Webinar Part 2                      

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for a two-part webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.

This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.

Learning Objectives

• Characterize the clinical and QOL burden of ER+/HER2- metastatic breast cancer.
• Explore the mechanisms of action of current therapies for ER+/HER2- metastatic breast cancer.
• Review the current treatment options for ER+/HER2- metastatic breast cancer and detail outcomes/survival associated with 2nd-line therapy.
• Describe therapeutics for metastatic breast cancer that target ERs, including PROTAC ER degraders.
• Outline payer strategies to facilitate precision oncology care for metastatic breast cancer with companion diagnostics.